Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both

New England Journal of Medicine

Volumn 335, Issue 6, 1996, Pages 392-398

  Havlir, Diane V ^a,k   Dubé, Michael P ^b   Sattler, Fred R ^b   Forthal, Donald N ^c   Kemper, Carol A ^d   Dunne, Michael W ^e   Parenti, David M ^f   Lavelle, James P ^g   White Jr , A Clinton ^h   Witt, Mallory D ⁱ   Bozzette, Samuel A ^a,j   Mccutchan, J Allen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ HARBOR UCLA MEDICAL CENTER   (United States)

^j RAND CORPORATION   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; FLUCONAZOLE; RIFABUTIN;

ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MIXTURE; DRUG SCREENING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LEUKOPENIA; MULTICENTER STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AZITHROMYCIN; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RIFABUTIN;

EID: 9344242918     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199608083350604     Document Type: Article

References (29)

1. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165: 1082-5.
2. Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T, Zidovudine Epidemiology Study Group. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992;146:285-9.
3. Horsburgh CR, Havlick JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991;144:557-9.
4. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural history of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991;164:994-8.
5. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: a randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121:905-11.
6. Dubé MP, Sattler F, Torriani F, et al. A randomized study of clarithromycin plus clofazimine, with or without ethambutol, for treatment and prevention of relapse of disseminated MAC (DMAC) in AIDS. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995. Washington, D.C.: American Society for Microbiology, 1995:241. abstract.
7. Berry A, Koletar S, Williams D. Azithromycin therapy for disseminated Mycobacterium avium-intracellulare in AIDS patients. In: Program and abstracts of the First National Conference on Human Retroviruses and Related Infections, Washington, D.C., December 12-16, 1993. Washington, D.C.: American Society for Microbiology, 1993:106. abstract.
8. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-33.
9. Masur H, Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. N Engl J Med 1993; 329:898-904.
10. Young LS, Wiviott L, Wu M, Kolonoski P, Bolan R, Inderlied CB. Azithromycin for treatment of Mycobacterium avium-intracellulare complex infection in patients with AIDS. Lancet 1991;338:1107-9.
11. Griffith DE, Wallace RJ Jr, Brown BA, Girard WM, Murphy DT, Onyi GO. Azithromycin (AZITH) monotherapy (MONO-Rx) for HIV (-) patients with Mycobacterium avium intracellulare complex (MAI) lung disease. Am J Respir Crit Care Med 1995;151:Suppl:A477. abstract.
12. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
13. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25: Suppl A:73-82.
14. Klemens SP, Cynamon MH. Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. Antimicrob Agents Chemother 1994;38:1721-5.
15. Havlir DV, Bozzette SA, McCutchan JA, Dunne M, CCTG/MOPPS Study Investigators. A double-blind, randomized study of weekly versus daily fluconazole (FLU) for the prevention of fungal infections in AIDS patients. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996. Alexandria, Va.: Infectious Diseases Society of America, 1996: 158. abstract.
16. Haviir D, Kemper CA, Deresinski SC. Reproducibility of lysis-centrifugation cultures for quantification of Mycobacterium avium complex bacteremia. J Clin Microbiol 1993;31:1794-8.
17. Heifets LB. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, Fla.: CRC Press, 1991.
18. Berry SH, Bozzette SA, Hays RD, Stewart AL, Kanouse DE. Measuring patient reported health status in advanced HIV disease: HIV-PARSE survey instrument. Santa Monica, Calif.: RAND Corp., 1994. (Publication no. MR-341-NIAID.)
19. Bozzette SA, Kanouse DE, Berry S, Duan N. Health status and function with zidovudine or zalcitabine as initial therapy for AIDS: a randomized controlled trial. JAMA 1995;273:295-301.
20. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
21. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44(RR-8):1-34.
22. Pierce M, Crampton S, Henry D, Craft C, Notario G. The effect of MAC and its prevention on survival in patients with advanced HIV infection. In: Late breaker abstract book of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995:11. Washington, D.C.: American Society for Microbiology, 1995:11. abstract.
23. Benson CA, Cohn DL, Williams P, ACTG 196/CPCRA 009 Study Team. A phase III prospective, randomized, double-blind study of the safety and efficacy of clarithromycin vs. rifabutin vs. clarithromycin plus rifabutin for prevention of Mycobacterium avium complex disease in HIV+ patients with CD4 counts less than or equal to 100 cells/μL. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996. Alexandria, Va.: Infectious Diseases Society of America, 1996:91. abstract.
24. Girard AE, Girard D, English AR, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 1987;31:1948-54.
25. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother 1995;39:2625-30.
26. Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993; 37:2364-70.
27. Oldfield EC, Dickinson G, Chung R, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, D.C., January 28-February 1, 1996. Alexandria, Va.: Infectious Diseases Society of America, 1996:90. abstract.
28. Havlir D, Torriani F, Dube M. Uveitis associated with rifabutin prophylaxis. Ann Intern Med 1994;121:510-2.
29. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-25.